ArticleEuropean journal of medical research2025
Differential impact of lipid levels on the association between homocysteine and new-onset atrial fibrillation in acute myocardial infarction patients.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHomocysteine (Hcy) and dyslipidemia are both established risk factors for cardiovascular disease. However, their interaction in the development of new-onset atrial fibrillation (NOAF) after acute myocardial infarction (AMI)-especially across different baseline LDL-C levels-is not well-understood.
methodsThis retrospective cohort study included 3,257 AMI patients. Within both normal lipid and dyslipidemia groups, participants were stratified by Hcy tertiles. Spearman correlation analysis was employed to examine the relationship between Hcy and lipid profiles. Multivariable logistic regression and generalized additive models with smooth curve fitting were utilized to investigate the association between Hcy levels and NOAF across varying baseline LDL-C profiles. Sensitivity and subgroup analyses confirmed the robustness of the findings.
resultsAnalysis of 3,257 AMI patients revealed significant lipid-dependent associations between Hcy levels and the risk of in-hospital NOAF. Specifically, in patients with normal lipid levels, elevated Hcy was an independent risk factor for NOAF: each 1 µmol/L increase in Hcy conferred a 3.1% higher risk (fully adjusted odds ratio [OR] 1.031, 95% confidence interval [CI] 1.019-1.043; P < 0.001). A similar significant trend (P for trend < 0.05) was observed when Hcy was categorized. Notably, a linear relationship between Hcy levels and NOAF risk was evident in the normal lipid group. In contrast, among patients with dyslipidemia, neither unadjusted nor fully adjusted models demonstrated a significant association between Hcy levels and NOAF risk (all P > 0.05). Furthermore, the smooth curve analysis indicated that within the dyslipidemia group, the relationship between Hcy and NOAF risk approximated a horizontal line, consistent with the logistic regression model. Sensitivity and subgroup analyses confirmed the robustness of the findings.
conclusionsThis study reveals that baseline lipid levels may modify the association between Hcy and NOAF in patients with AMI. Specifically, Hcy was associated with an increased risk of in-hospital NOAF in AMI patients with normal lipid profiles, whereas this association was not observed in those with dyslipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.